N/A N=258 Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
Lung Nodule
Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Application of 3D Printing Technique in Small Pulmonary Nodule Localization
Lung Neoplasm · Thoracic Surgery, Video-Assisted
Primary: Accuracy of Lung Nodule Localization — 9.6; 8.7 mm
N/A N=50 Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules
Signs and Symptoms
Primary: Sensitivity — 53 percentage of positive scans
Phase 2 N=25 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions
Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants
Phase 2 N=98 Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules
Current Smoker · Former Smoker · Multiple Pulmonary Nodules
Primary: Change in the Sum of Longest Diameters of Baseline Target Nodules (Person-specific Analysis) — 0.3; -0.12 millimeter (mm)
Phase 2 N=15 18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Cigarette Smoker · Current Smoker · Former Smoker
Primary: Diagnostic Performance Metrics (Sensitivity, Specificity, PPV, NPV, and Accuracy) of Ultrasonography and Capnography for Malignant Lung Nodules — 100; 70; 100; 100…
Phase 2 N=202 Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer
Lung Cancer
Primary: Number CT- Detected Lung Nodules by Participant — 12; 14; 26; 19 lung nodules
Phase 2 N=100 OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Lung Neoplasms · Lung Cancer
Primary: Sensitivity or True Positive Rate (TPR) — 0.854 proportion of lesions
N/A N=23 iNod System Human Feasibility Assessment
Solitary Pulmonary Nodule · Biopsy, Fine-Needle
Primary: Acquisition of Adequate Specimens of Targeted Lung Lesions — 9 Participants
N/A N=105 Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling
Lung Cancer
Primary: Safety Measurement — 0; 0; 0; 0 Adverse events
N/A N=24 Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy
Peripheral Pulmonary Nodules
Primary: Feasibility — 24 participants
Phase 3 N=112 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Lung Neoplasms · Lung Cancer
Primary: Clinically Significant Events (CSE) — .530 proportion of participants
N/A N=12 Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC
Lung Cancer
Primary: Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules — 3612; 3735; 1283; 1548 CT-case | nodule — p=<0.05
Phase 3 N=53,454 National Lung Screening Trial (NLST) Screening
Lung Cancer
Primary: Lung Cancer Deaths — 356; 443 Participants — p=0.004
N/A N=30 InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
Lung Cancer
Primary: The Ability of BioSpy System to Acquire Electrophysiological Measurements in the Relevant Tissues During Bronchoscopic Biopsy. — 26 Participants
N/A N=30 Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter
Cancer, Lung · Cancer, Metastatic to Lung
Primary: Number of Participants With AEs Related to the Emprint™ Ablation Catheter Kit With Thermosphere™ Technology — 1 Participants
N/A N=76 National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants
Phase 2 N=40 Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8
Primary: 6-month CT Assessment (Tumor Response Per mRECIST) — 1; 36; 2; 1 Participants
N/A N=1,200 Patient Navigation for Lung Screening at MGH Community Health Centers
Lung Cancer
Primary: Chest CT Completion — 124; 138 Participants
N/A N=25 Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
N/A N=25 EPIONE Guided Lung Evaluation
Lung Cancer
Primary: Feasibility of the Device — 26 Number of targets reached
Phase 1 N=9 Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
Pulmonary Nodule
Primary: Feasibility of Ultra Short-term Steroid Therapy to Increase the Accuracy of FDG-PET/CT Imaging — 3.97; 4.27 gm/ml
Phase 2 N=128 Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Determine the Clinical Sensitivity and Specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay Using Sputum Specimens From Two Cohorts of Participants and…
N/A N=20 EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer
Non Small Cell Lung Cancer · NSCLC
Primary: Feasibility of Utilizing Endobronchial Ultrasound Guided Miniforceps as Assessed by the Number of Participants From Whom Adequate Amounts of Tissue to Perform PD-L1…
Phase 1 N=33 Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Clinical Response as Assessed Metabolically by Changes in Positron Emission Tomography (PET) Scan Between Baseline and Immediately Prior to Surgery. — 78; 64; 50; 22…
Phase 2 N=46 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
Lung Carcinoma · Solitary Pulmonary Nodule · Cigarette Smoking Behavior
Primary: Ability of 18F-FSPG PET/CT to Discriminate Benign From Malignant Nodules — 0.706; 0.778; 0.731; 0.817 proportion, range 0 to 1, higher better
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
N/A N=55 Robotic Bronchoscopy for Peripheral Pulmonary Lesions
Lung; Node
Primary: Number of Participants With Device or Procedure Related Adverse Events — 2 Participants
Phase 2 N=40 Phase 2 Study of VGT-309 in Lung Cancer
Lung Cancer
Primary: Clinically Significant Event (CSE) — 0.425 Proportion of subjects — p=< .0001
N/A N=420 A Multi-Center Trial of the ProLung Test™
Solitary Pulmonary Nodule · Multiple Pulmonary Nodules
Primary: Clinical Efficacy in the Risk Stratification of Patients With Indeterminate Lesions — 70.37; 46.97; 68.47; 49.21 percentage